![]() All received diet counseling to reduce their calorie intake by about 500 a day. ![]() Many qualified as obese, while others were overweight but also had such risk factors as high blood pressure, high cholesterol levels, cardiovascular disease or obstructive sleep apnea. The Eli Lilly study lasted 72 weeks and involved 2,539 participants. Many people who could most benefit from weight loss may be unable to afford such expensive drugs. Kushner said.Įxperts worry that tirzepatide, if approved, might carry a price in the same range. With the Eli Lilly drug and Novo Nordisk’s semaglutide, which was recently approved, “we really are on the cusp of a new way of treatment,” Dr. But many people are ineligible or simply do not want the surgery. The only other treatment is bariatric surgery, which can result in substantial weight loss. That is enough to improve health, but not nearly enough to make a big difference in the lives of peoples who are obese. Kushner, an obesity expert at Northwestern University’s Feinberg School of Medicine and a paid consultant to Novo Nordisk, said the new drug along with a similar but less effective one by Novo Nordisk, can close a so-called treatment gap.ĭiet and exercise, combined with earlier obesity drugs, usually yield perhaps a 10 percent weight loss in patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |